View Full Version : how her2+breast cancer subtypes differ(and why some respond better2 targeted therapy
I have previously commended Maurizio Scaltriti, who did the original preclinical research showing the supersynergism of herceptin plus lapatinib --the basis for the neoadjuvant studies and for the combined treatment many of you have benefitted from
http://www.readcube.com/articles/10.1002/path.4269?locale=en
tricia keegan
10-12-2013, 04:14 PM
Lani I had trouble reading this, would you mind condensing it for me please??
'lizbeth
10-12-2013, 04:20 PM
I had a similar problem, after the abstract the pages were blurred. I'm sure the information is fascinating. I second Tricia's request.
linn65
10-14-2013, 08:12 AM
My iPad wouldn't open this article, but I would like a analogy I am sure....I think Lani should just write a page and then list the article for super science genius people to read if they like!
vBulletin® v3.8.7, Copyright ©2000-2026, vBulletin Solutions, Inc.